AI Article Synopsis
Article Abstract
Objective: Racial/ethnic minorities experience more severe outcomes of coronavirus disease 2019 (COVID-19) in the general US population. This study was undertaken to examine the association between race/ethnicity and COVID-19 hospitalization, ventilation status, and mortality in people with rheumatic disease.
Methods: US patients with rheumatic disease and COVID-19 were entered into the COVID-19 Global Rheumatology Alliance physician registry between March 24, 2020 and August 26, 2020 were included. Race/ethnicity was defined as White, African American, Latinx, Asian, or other/mixed race. Outcome measures included hospitalization, requirement for ventilatory support, and death. Multivariable regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) adjusted for age, sex, smoking status, rheumatic disease diagnosis, comorbidities, medication use prior to infection, and rheumatic disease activity.
Results: A total of 1,324 patients were included, of whom 36% were hospitalized and 6% died; 26% of hospitalized patients required mechanical ventilation. In multivariable models, African American patients (OR 2.74 [95% CI 1.90-3.95]), Latinx patients (OR 1.71 [95% CI 1.18-2.49]), and Asian patients (OR 2.69 [95% CI 1.16-6.24]) had higher odds of hospitalization compared to White patients. Latinx patients also had 3-fold increased odds of requiring ventilatory support (OR 3.25 [95% CI 1.75-6.05]). No differences in mortality based on race/ethnicity were found, though power to detect associations may have been limited.
Conclusion: Similar to findings in the general US population, racial/ethnic minorities with rheumatic disease and COVID-19 had increased odds of hospitalization and ventilatory support. These results illustrate significant health disparities related to COVID-19 in people with rheumatic diseases. The rheumatology community should proactively address the needs of patients currently experiencing inequitable health outcomes during the pandemic.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467766 | PMC |
| http://dx.doi.org/10.1002/art.41567 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preclinical RA: How to halt its progression.
Best Pract Res Clin Rheumatol
December 2024
Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 97239, USA; Rheumatology Section, VA Portland Health Care System, Portland, OR, 97239, USA. Electronic address:
Rheumatoid arthritis (RA) is a chronic autoimmune disorder with a complex pathogenesis that evolves through various stages before clinical symptoms emerge. This review outlines the natural history of RA, starting from genetic predisposition and environmental triggers to preclinical autoimmunity and subsequent joint inflammation. Key genetic factors interact with environmental elements like smoking and infections, producing autoantibodies such as anti-citrullinated protein antibodies (ACPA) and rheumatoid factor, which precede clinical manifestations by several years.
View Article and Find Full Text PDFWhite Blood Cell Count and Lymphocyte-to-monocyte Ratio as a Screening Tool for Predicting Intravascular Lymphoma in the Differential Diagnosis of Fever of Unknown Origin.
Intern Med
December 2024
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Japan.
Objective Intravascular large B-cell lymphoma (IVLBCL) is a critical cause of fever of unknown origin (FUO). While a pathological analysis is essential for diagnosing IVLBCL, the indications for an invasive procedure may be ascertained using easy, non-invasive tests. The lymphocyte-to-monocyte ratio (LMR) can reportedly predict the diagnosis of malignant lymphoma in patients with lymphadenopathy; however, its clinical utility in predicting an IVLBCL diagnosis in patients with FUO remains to be elucidated.
View Article and Find Full Text PDFValidity and reliability of the Japanese version of the ACE tool for assessing evidence-based medicine competencies in medical practitioners and students: An evaluation in an online setting.
Intern Med
December 2024
Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine/Public Health, Japan.
Introduction Evidence-based medicine (EBM) competency is crucial for healthcare professionals; however, validated tools to assess EBM skills in Japanese are scarce. This study aimed to develop and validate a Japanese version of the Assessing Competency in EBM (ACE) tool. Methods We translated the ACE tool into Japanese, following international standards, and distributed it online to 99 healthcare professionals and students.
View Article and Find Full Text PDFJapanese Spotted Fever with Severe Myositis: A Diagnostic Challenge.
Intern Med
December 2024
Department of Internal Medicine, Kurashiki Medical Center, Japan.
A woman in her late 70s presented with a fever, rashes, and marked proximal muscle weakness. Noninfectious conditions, including myositis and vasculitis, were initially considered. Treatment with cephalosporins was ineffective, but the symptoms improved with minocycline, indicating possible Japanese spotted fever (JSF) despite no apparent history of tick exposure.
View Article and Find Full Text PDFInnovations in aggregation-induced emission materials for theranostics in the musculoskeletal system.
Biosens Bioelectron
December 2024
Department of Sports Medicine, Huashan Hospital, Fudan University, No.12 Urumqi Middle Rd., Shanghai, 200040, China. Electronic address:
Aggregation-induced emission (AIE) offers a promising solution for achieving lower background and more reliable signals in biomedical imaging. AIE materials also exhibiting photostability and resistance to photobleaching. These characters are crucial for monitoring musculoskeletal functions and offering targeted therapies for related diseases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!